🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Heading to #ASCO23? Want to get a head start on meeting content on your flight to Chicago? The ASCO website is mostly organized w hyperlinks, but you can download by track ahead of time and review the abstracts wout wifi here: conferences.asco.org/am/abstracts-p……See everyone soon!

📣 Shout out to Laurence Albiges for intiating this ambitious trial in #RCC on a European scale 🇪🇺 #CARE1

👏👏👏 AERIO 😷💉💉💉 pour toujours plus de formations transversales en partenariat avec les autres spécialités, ce soir AFUF !

Efficacy of sacituzumab govitecan according to Trop-2 expression in mUC. Very interesting to see that no correlation was seen for ORR, PFS or OS and Trop-2 expression #ASCO23

Filling the gap for ncc-RCC ? Doublets (& careful triplet) are coming but one size does not fit all. #ASCO2023

Great debate this morning on relapsed #NSGCT between Dr Kollmannsberger and Edmund Waller. 🐯TIGER results even more eagerly awaited ! One certitude: these pts MUST be referred to high-volume centres !

📣 New data from #PEACE1 Great presentation by Alberto Bossi. Synergistic effect of Abi and prostate RT Gustave Roussy

Congrats to the #TALAPRO2 team — talazoparib and enzalutamide are significantly active in patients w HRR alterations!! Important piece of the HRR story in #prostatecancer. #ASCO23

⏰Early but worthwhile !! Congratulations Yohann Loriot 👏👏👏 🧬ALL mUC patients should be tested for FGFR alterations, as soon as possible following diagnosis. #THOR #ASCO23 Gustave Roussy

🗞️In FR press today:insight into the daily life of a patient receiving Erda in #THOR since 2021 for mUC 👏Kudos to her for having the courage to contribute her voice & thks to pts who enroll in clin. trials 💊Now waiting for approval EU Medicines Agency ANSM Haute Autorité de santé Yohann Loriot #ASCO23

✨✂️ Inauguration du nouveau "Gard" ! Un service adapté à l'oncologie de 2023 pour une meilleure qualité de vie à l'hôpital pour les patients comme les soignants🎗️Bientôt aussi un nouvel espace pour les jeunes adultes atteints de cancer. Gustave Roussy #AYACancer #SeptembreEnOr

Great news for pts with mUC!! Another question is the benefit of combos (some -ve trials) and by extent the best agent to combine with. Results from EV-302 (EV Pembro vs Chemo) eagerly awaited, especially for cisplatin-ineligible pts.

Congratulations Luca Antonelli for leading this collaborative work, highlighting as always the need of an experienced multidisciplinary team for mGCTs management.

📣Great news: 🏆ADC/IO (EV/Pembro) combo outperforms chemo in 1L for la/mUC ! EV-302 shows OS+PFS "clinically meaningful" benefit. Waiting for the details ! Yohann Loriot OncoAlert Uromigos Gustave Roussy ESMO - Eur. Oncology Presse release: prnewswire.com/news-releases/…

Adverse Health Outcomes and Global Quality of Life in Long-term Testicular Cancer Survivors: A longitudinal 30-year perspective: 🔘Testicular cancer survivors (TCS) who received high doses of cisplatin chemotherapy are at high risk for long-term side effects and reduced quality

Happiest 81st Birthday Dr. Lawrence Einhorn! 🎂🥳 Thank you for the amazing development of the curated chemotherapy regimens and RPLND surgical techniques for testicular cancer. You have saved so many lives and we are most grateful!! See you next month at our Testicular Cancer

#Movember Premier jour 🪒 L'occasion d'en savoir plus sur la prévention et le traitement des cancers masculins qui nous occupent toute l'année. En parler c'est déjà agir ! Gustave Roussy Cerhom Movember France Olivier JÉRÔME Stephane BEAUMONT #DoYouMovember

En direct du premier séminaire @GroupeUnicancer cancérologie outre-mer merci au MOM pour l’accueil Ministère de l'Intérieur et Mr le ministre P Viguier: réduire les inégalités d’accès aux soins onco une priorité Gustave Roussy Fabrice Barlesi Jean-Yves Blay Institut national du cancer